Symptom Checklist for Numbness in People With Endometrial Cancer: Distinguishing Treatment-Related Neuropathy, Disease-Related Complications, and Urgent Red Flags

Numbness in endometrial cancer can arise from chemotherapy-induced peripheral neuropathy, immune therapy effects, or less commonly from cancer-related nerve or spinal cord compression. A well-structured checklist helps separate likely treatment side effects from disease complications and flags symptoms that need urgent care. Below is a practical, patient-friendly checklist built from established descriptions of chemotherapy-induced neuropathy and cancer-related neurologic emergencies, along with guidance on when to call the care team immediately. Chemotherapy with taxanes (paclitaxel) and platinums (carboplatin/cisplatin) commonly causes tingling, numbness, burning pain, and dexterity or balance problems, and these symptoms often peak within months after treatment and may slowly improve after therapy ends. ^{[1] [2]} Such neuropathy typically starts in fingers and toes (“glove and stocking” pattern), may worsen with cumulative dosing, and can interfere with fine motor tasks like buttoning or picking up small objects. ^{[3] [2]}

---

How to Use This Checklist

• Check the boxes that match your symptoms and details.
• Share the completed checklist with your oncology team.
• Any item marked “Urgent red flag” warrants same‑day contact with your care team or emergency evaluation.

---

A. Symptom Basics

• Location of numbness/tingling: fingers, toes, hands, feet; other areas (specify). Chemotherapy neuropathy most often affects hands and feet symmetrically. ^[3]
• Sensation quality: tingling/pins-and-needles, numbness/loss of feeling, burning/shooting/stabbing pain. These are classic neuropathy symptoms. ^{[3] [4]}
• Onset and timing: started during chemotherapy, after several cycles, after completing treatment, or new without recent treatment. Neuropathy commonly develops during treatment, can worsen with repeated doses, and often peaks 3–5 months after the last chemotherapy. ^{[5] [6]}
• Pattern: gradual progression vs sudden onset. Chemotherapy neuropathy usually builds gradually; sudden severe changes are less typical and may require prompt evaluation. ^[5]
• Symmetry: both sides vs one side only. Treatment neuropathy is often symmetric; asymmetric focal deficits can suggest other causes. ^[2]
• Functional impact: trouble buttoning, picking up small objects, walking, balance, falls. Difficulty with fine motor tasks and balance is common in neuropathy. ^{[1] [3]}

---

B. Treatment Context

• Current or recent drugs:
  • Paclitaxel or docetaxel (taxanes). Taxanes commonly cause peripheral neuropathy that is dose-related. ^[2]
  • Carboplatin or cisplatin (platinum drugs). Platinum agents can cause sensory neuropathy that may be cumulative. ^[2]
  • Immunotherapy (e.g., durvalumab, dostarlimab) combined with chemotherapy. Report new neurologic symptoms promptly during these regimens. ^{[3] [7]}
• Time since last infusion: days/weeks/months. Neuropathy can be most severe soon after dosing and can peak months after finishing therapy; improvement, if it occurs, is gradual. ^{[5] [6]}
• Past neuropathy with earlier cycles or prior lines of therapy. Previous exposure to neurotoxic drugs can influence risk and course. ^[2]
• Other causes: diabetes, alcohol use, vitamin deficiencies, thyroid disease. These conditions can contribute to neuropathy and should be considered alongside treatment effects. ^[4]

---

C. Features Suggesting Treatment‑Related Peripheral Neuropathy

• “Glove and stocking” distribution in hands and feet, often symmetric. ^[2]
• Tingling, pins-and-needles, numbness, or burning pain that gradually appeared during or after chemotherapy. ^{[3] [5]}
• Worsens with cumulative doses or is most intense right after a cycle, with partial easing before the next dose. ^[5]
• Functional issues with fine motor tasks (buttons, small objects) or balance due to sensory loss. ^{[1] [3]}
• Peak symptom intensity within 3–5 months after completing chemo, with slow improvement over months (sometimes incomplete). ^[6]

If most of your answers align with this pattern, the symptoms may be consistent with chemotherapy-induced peripheral neuropathy rather than direct tumor-related nerve compression. ^{[2] [3]}

---

D. Features Raising Concern for Disease‑Related Neurologic Complications

• New focal weakness in an arm or leg, or rapidly worsening weakness. These may indicate nerve root or spinal cord involvement. ^[8]
• Numbness that climbs upward from the feet or occurs in a band-like level on the trunk. Spinal cord compression can cause segmental sensory changes and progressive weakness. ^{[9] [8]}
• Severe back pain (often worse at night), especially if new for you, with subsequent weakness or numbness. Spinal tumors often start with back pain and later cause weakness and numbness. ^{[9] [10]}
• Bowel or bladder changes (new incontinence, difficulty starting urination) with leg numbness/weakness. This pattern can signal spinal cord compression and needs urgent evaluation. ^[8]
• Asymmetry (one-sided symptoms), sudden onset, or rapidly progressive deficits. Asymmetric or rapidly worsening symptoms are less typical for routine chemo neuropathy. ^{[2] [8]}

These features do not prove tumor involvement but increase concern for disease-related causes and merit prompt assessment. ^{[9] [10]}

---

E. Urgent Red Flags Requiring Same‑Day Contact or Emergency Care

• Severe or rapidly worsening weakness in legs or arms. Spinal cord or nerve compression can quickly progress and requires urgent treatment. ^{[9] [8]}
• New problems with walking, frequent falls, or inability to stand without help. Progressive neurologic impairment may indicate compression. ^[8]
• New loss of bowel or bladder control, or urinary retention. These can reflect spinal cord compression and are emergencies. ^[8]
• Severe midline back pain (especially night pain) with new neurologic deficits. Pain that precedes weakness/numbness is classic for spinal compression. ^{[9] [10]}
• Neurologic symptoms with fever, severe headache, stiff neck, confusion, drowsiness, or loss of consciousness while on chemo‑immunotherapy. Such systemic neurologic signs can represent serious immune‑related or infectious complications and require immediate care. ^[7]
• Sudden onset of severe numbness, facial droop, slurred speech, or visual changes. Sudden focal neurologic deficits are not typical of gradual chemo neuropathy and need emergency evaluation. ^[8]

---

F. Safety Tips for Living With Neuropathy

• Protect numb hands/feet: test bath water with elbow, use oven mitts/pot holders, wear rubber-soled shoes, and keep floors well lit and clutter-free to prevent burns and falls. These practical measures reduce injury when sensation is reduced. ^{[1] [3]}
• Pace activities and use handrails; consider physical therapy for balance and strength if neuropathy affects gait. Rehabilitation support can help maintain function and safety. ^[11]
• Tell your oncology team about any new or worsening symptoms promptly, especially during combination chemo‑immunotherapy. Early reporting allows dose adjustments and supportive care. ^[3]

---

G. Example Patient Checklist (Printable)

• Current treatment:
  • Paclitaxel (yes/no), Carboplatin (yes/no), Cisplatin (yes/no), Immunotherapy (durvalumab/dostarlimab) (yes/no), Other (list). ^{[2] [3]}
  • Last dose date: ____; Number of cycles: _____. Neuropathy may worsen with cumulative dosing and peak months after completion. ^{[5] [6]}
• Symptom location: fingers/toes/hands/feet/other; symmetric (yes/no). Symmetric distal symptoms suggest treatment neuropathy. ^[2]
• Sensation type: tingling/pins-and-needles; numbness/loss of feeling; burning/shooting pain. These are typical features of peripheral neuropathy. ^{[3] [4]}
• Onset and course: gradual during treatment; peaked after finishing; sudden onset. Chemo neuropathy usually develops gradually and can peak months after therapy. ^{[5] [6]}
• Functional impact: difficulty with buttons, small objects, writing; balance problems; falls. Fine-motor and balance issues commonly occur with neuropathy. ^{[1] [3]}
• Pain severity (0–10): ____; Worse at night (yes/no). Neuropathic pain often worsens at night. ^[4]
• Co-conditions: diabetes, thyroid disease, vitamin deficiencies, alcohol use (yes/no). These can contribute to neuropathy. ^[4]
• Red flag screening (any “yes” = urgent):
  • New or rapidly worsening weakness in legs/arms (yes/no). Weakness with back pain can signal cord compression. ^{[9] [8]}
  • New severe back pain, worse at night (yes/no). Night pain with progressive neurologic signs is concerning. ^{[9] [10]}
  • New bowel/bladder incontinence or retention (yes/no). Urgent evaluation is required. ^[8]
  • Sudden one‑sided numbness/weakness, facial droop, speech problems, or vision changes (yes/no). Sudden focal deficits need emergency care. ^[8]
  • Fever, severe headache, stiff neck, confusion, drowsiness, or loss of consciousness while on chemo‑immunotherapy (yes/no). These can be serious treatment-related complications. ^[7]

---

H. Why This Matters Clinically

• Taxane- and platinum-based regimens commonly used for recurrent or metastatic endometrial cancer are well known to cause peripheral neuropathy, with tingling, numbness, pain, and functional difficulties in daily tasks. Recognizing this pattern helps guide supportive care and treatment adjustments. ^{[1] [3]}
• Neuropathy severity often correlates with cumulative exposure and may slowly improve after therapy, although some symptoms can persist. Setting expectations helps with monitoring and rehabilitation planning. ^{[2] [6]}
• A minority of cases reflect disease-related nerve or spinal cord involvement; identifying warning signs like progressive weakness, back pain with neurologic changes, or bowel/bladder dysfunction ensures timely imaging and intervention. ^{[9] [10]}

---

I. When to Contact Your Team

• Report any new numbness, tingling, pain, or functional changes during or after chemotherapy. Early communication allows dose modifications and supportive strategies. ^[3]
• Seek urgent care for any red flags listed above, especially new weakness, back pain with neurologic symptoms, bowel/bladder changes, or sudden focal deficits, as these can represent neurologic emergencies. ^{[9] [8]}

---

Quick Reference Table

Checklist Domain	Findings suggesting treatment-related neuropathy	Findings suggesting disease-related complication	Urgent red flags
Distribution	Symmetric hands/feet (“glove and stocking”)	Asymmetric, focal, or ascending band-like level	Sudden asymmetric deficit or rapidly worsening pattern
Onset/course	Gradual during chemo; peaks months after; may slowly improve	Progressive with new back pain or focal deficits	Rapid progression or sudden onset
Symptoms	Tingling, numbness, burning pain; fine-motor issues, balance troubles	Weakness, sensory level, radicular pain	New weakness, falls, bowel/bladder issues, severe night back pain
Treatment link	Taxane/platinum exposure; cumulative dosing	Not clearly linked to dosing; associated with tumor burden/location	Any severe neuro change during therapy, especially with systemic symptoms
Action	Report; consider dose adjust, safety measures, rehab	Prompt clinic evaluation and imaging as indicated	Same-day oncology contact or emergency care

Treatment-related neuropathy often presents with distal symmetric sensory symptoms and functional difficulty in fine motor tasks, while disease-related complications more often include new focal weakness, severe back pain, and bowel/bladder involvement features that demand urgent evaluation. ^{[3] [9]}